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Abstract
The photoreceptor cells in the retina have a highly specialized sensory cilium, the outer segment, 
which is important for detecting light. Mutations in cilia related genes often result in retinal 
degeneration. The ability to reprogram human cells into induced pluripotent stem cells (iPSCs) 
and then differentiate them into a wide range of different cell types has revolutionized our ability 
to study human disease. To date, however, the challenge of producing fully differentiated 
photoreceptors in vitro has limited the application of this technology in studying retinal 
degeneration. In this review we will discuss recent advances in stem cell technology and 
photoreceptor differentiation. In particular, the development of photoreceptors with rudimentary 
outer segments that can be used to understand disease mechanisms and as an important model to 
test potential new therapies for inherited retinal ciliopathies.
Introduction: the retina and specialized cilia
The retina is responsible for transducing light into an electrochemical signal and 
transmitting that signal to the brain. It is comprised of around 55 neuronal subtypes, which 
all have different functions to allow the propagation of the light signal [1]. The cells in the 
retina that detect light are the photoreceptors, consisting of two types: cones and rods. Cones 
are responsible for daytime and colour vision in humans, whereas rod cells detect much 
lower levels of light and are therefore important for night vision. Photoreceptors possess a 
highly specialised sensory cilium known as the outer segment (OS). The OS consists of 
tightly packed membranous discs laden with photoresponsive opsin proteins as well as other 
components of the phototransduction machinery. The OS is joined to the biosynthetic inner 
segment (IS), which contains the endoplasmic reticulum (ER), by the connecting cilium 
(CC), a specialized cilia transition zone. The apical 10% of rod OS discs are shed daily and 
phagocytosed by the overlying retinal pigment epithelium (RPE) [2]. All the components 
needed for the assembly, maintenance and continuous turnover of the OS are synthesised in 
the IS and transported through the CC via the intraflagellar transport (IFT) machinery [3].
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Cilia are microtubule-based organelles that project from the surface of eukaryotic cells. They 
are present from the earliest stages of development through to highly differentiated cells in 
adult tissues. Once thought to be a vestigial organelle they are now known to have an 
important function as sensors relaying information from the extracellular environment. 
Ciliopathies are a relatively recently defined class of inherited disorders that involve aberrant 
ciliary function [4]. The clinical manifestations of this dysfunction range from single organ 
involvement, such as retinitis pigmentosa (RP) to multi-organ involvement and syndromic 
disease, affecting a broad range of organs including the central nervous system, kidneys and 
adipose tissue [5]. Ciliopathy genes encode structural or functional components of the cilia 
or their basal bodies. Perhaps as a consequence of the high protein-trafficking load through 
the photoreceptor CC, the retina is possibly the most commonly affected organ [6].
Photoreceptor degeneration is a major cause of blindness. There are over 250 different 
causative genes identified to date (RetNet; https://sph.uth.edu/retnet/). Forms of inherited 
retinal dystrophy include RP and Leber congenital amaurosis (LCA). RP is a group of 
heterogeneous retinal dystrophies that usually involves progressive rod cell degeneration 
with secondary cone death. RP affects around 1:4000 individuals worldwide, leading to 1.5 
million affected patients [7]. RP often does not present until the second decade; however X-
linked forms of the disease can result in early onset degeneration. For example, mutations in 
the cilia-associated gene RP2 (retinitis pigmentosa 2; OMIM 312600) result in X-linked RP 
[8]. In addition to the rod degeneration usually seen in RP patients, some RP2 patients may 
also have a macular atrophy leading to decreased visual acuity in childhood [9]. LCA is an 
early onset retinal degeneration characterised by profound visual impairment or loss in early 
childhood [10]. LCA accounts for 5% of all inherited retinal dystrophies and affects up to 
1:30000 patients [10]. LCA is also highly heterogeneous; there are currently 13 known 
genetic loci for LCA (RetNet) affecting different retinal functions. One of the most 
commonly mutated genes is CEP290 (centrosomal protein of 290kDa; OMIM 611755), 
accounting for around 15-25% of LCA cases [11]. Here, we will mainly focus on RP2 and 
CEP290 retinal ciliopathies.
RP2 and CEP290
RP2 is a GTPase activating protein (GAP) for the essential cilia-related GTPase, Arl3 
[12,13]. RP2 is a ubiquitously expressed protein; in the retina it is predominantly localized 
at the plasma membrane [14]. However there is a pool of RP2 that localizes to the basal 
body of the cilia in photoreceptors, suggesting a role in cilia protein trafficking [14,15]. 
Mutations in RP2 account for approximately 15% of X-linked RP cases [8]. In particular, 
nonsense mutations are relatively frequent in RP2 patients, such as the R120X mutation 
[16].
Animal models of RP2 have reported conflicting phenotypes. For example, morpholino 
knockdown of RP2 in zebrafish produces a range of severe developmental eye defects, from 
small eyes to delayed/defective retinal lamination and photoreceptors with no outer 
segments and multiple systemic developmental defects [17–19]. However, an RP2 knockout 
zebrafish had mild retinal degeneration associated with disruption of GRK1 and rod 
transducin, but displayed no overt systemic phenotype [20]. RP2 knockout mouse models 
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have produced some conflicting retinal phenotypes as well; cone opsin mis-localisation was 
observed in one model [21], whereas normal cone opsin traffic but abnormal traffic of 
prenylated phototransduction proteins PDE6-γ and GRK1 was observed in another [22]. 
Given the range of conflicting phenotypes reported in animal models, investigating actual 
human RP2 mutations in retinal cells derived from patients provides a new opportunity to 
gain insight into human disease mechanisms.
CEP290 is a protein found in all ciliated cells at the transition zone between the basal body 
and axoneme, and is essential for ciliogenesis [23,24]. A recent study utilising super-
resolution microscopy located CEP290 as a hub on which other transition zone proteins 
assemble and postulated that these are involved in the formation of Y-links bridging the 
ciliary membrane and the axoneme [25]. Mutations in CEP290 are associated with numerous 
syndromic ciliopathies, yet non-syndromic LCA is the most common outcome [26,27]. The 
majority of CEP290 LCA patients (86%) have at least one copy of the most common 
CEP290 mutation, a deep intronic c.2991+1665A>G change which leads to mis-splicing and 
inclusion of a stop-codon containing cryptic exon in CEP290 mRNA [27,28]. There is still 
some correct splicing of exons 26 to 27, such that this intronic mutation leads to reduced 
CEP290 protein levels and behaves as a hypomorph.
The rd16 mouse model contains an inframe deletion in Cep290 that produces a truncated 
protein. rd16 mice have considerable deterioration of rod and cone function at p18 a reduced 
outer nuclear layer and OS degeneration [23]. A Cep290 knock out (null) mouse has no OS 
formation and no surviving photoreceptors at p28, the majority of these knockouts died of 
hydrocephalus [6]. A humanised mouse model of the CEP290 deep intronic mutation 
resulted in the creation of a separate, distinct cryptic exon not seen in human cells [29], 
highlighting the difficulties of modelling some mutations in mice to investigate human 
disease mechanisms. Therefore, differentiating patient induced pluripotent stem cells 
(iPSCs) to photoreceptors may be the only route by which to recapitulate the mechanisms of 
CEP290 LCA.
Using iPSCs to model retinal degeneration
Much recent work has focused on the role of iPSCs as a model of disease and as a potential 
route for therapy. Stem cells are an appealing approach to disease modelling, due to their 
pluripotent nature that allows them to differentiate into multiple cell types, coupled to the 
presence of the disease associated changes in the correct genomic and cellular context [30]. 
iPSCs were first described in 2006 and have since been used as models in a plethora of 
diseases [31,32]. Indeed, the generation of iPSCs and subsequent differentiation into retinal 
cell types from patients allows the study of mutations causing retinal degeneration in a 
human cell and mutation-specific paradigm [33]. Initial methods focused on creating pure, 
single cell-type cultures; for example, many studies have concentrated on differentiating 
iPSCs into RPE cells, which can be achieved in a two-dimensional culture system [34–36]. 
This approach has successfully resulted in insights into disorders affecting the RPE; for 
example, RPE cells have been differentiated from patients with mutations in MERTK [37], 
RPE65 [38], BEST1 [39], and OAT1 [40]. Retinal-progenitor and rod-like cells have been 
created from RP patients with mutations in the rhodopsin gene that were reported to 
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recapitulate the disease phenotype; however, these progenitor cells were developmentally 
too immature to have OS containing rhodopsin [41,42].
3D ‘organoids’
Increasingly researchers are using three-dimensional organoid models derived from iPSCs to 
model disease tissue [43]. Organoid culture from iPSCs allows the creation of multiple cell-
types in a more natural, organised cellular environment [44,45]. The retina has been 
successfully modelled in this way [46,47]. Multiple groups have achieved the generation of 
self-organising three-dimensional optic cup structures derived from human embryonic stem 
cells (ESCs) and iPSCs that develop cells with all the characteristics of photoreceptor 
precursors [48–50]. This technology will allow greater insight into the consequence of 
retinal-dystrophy mutations in highly specific cellular and genetic context. However, these 
studies did not produce photoreceptors with morphologically distinct OS, limiting their 
application to study retinal ciliopathies.
Transplantation into a host retinal context appears to enhance the differentiation of these 
organoid produced photoreceptor progenitors, as shown with mouse ESC [51] or human 
iPSC [52]. Patient iPSC-derived optic cup-like structures and their transplantation were used 
to probe a novel intronic mutation in USH2A that causes RP [52]. Recently, we have used 
these methods of 3D optic cup differentiation to produce photoreceptors with 
morphologically distinct rudimentary OS in vitro, without the need for transplantation [53]. 
These iPSC-derived OS take up to 20 weeks to develop and express rod and cone opsins 
([53]; Figure 1). Furthermore, the CC can be visualised with a variety of cilia markers. 
Therefore, we can now use these 3D optic cups to probe retinal ciliopathy disease 
mechanisms and test potential therapies.
Retinal disease mechanisms and therapeutic development using iPSCs
Advances in gene-editing technology, such as the clustered regularly interspaced short 
palindromic repeats (CRISPR)/Cas system, could allow for the correction of gene defects 
before organoid culture and potentially individual cell replacement therapy in the ultimate 
personalised medicine [54]. iPSC-derived disease cells can also be used to test small 
molecule based approaches that are either mutation or gene specific that cannot easily be 
tested in animal models. For example, translational read-through inducing drugs (TRIDs) 
that read-though premature termination mutations in a range of genes, or antisense 
oligonucleotides (AONs) to correct mis-splicing events require the specific gene and cellular 
context that iPSC-derived cells and organoids can provide.
We have used X-linked RP patient-iPSCs to produce RPE cells with the RP2 R120X 
mutation, which results in a premature stop and loss of RP2 protein from the basal body 
[55]. The loss of RP2 had no effect on cilia length or incidence, but IFT20 was dispersed in 
the RP2 patient RPE, suggesting RP2 may be involved with the cilia-based trafficking of a 
specific group of cilia proteins. Indeed, the traffic and membrane association of the beta 
subunit of transducin (Gβ1) was also disrupted [55,56]. Importantly, we were able to reverse 
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these phenotypes using TRIDs, by restoring the RP2 protein levels up to 20% of normal in 
the RPE cells [55].
More recently, we used patient-derived iPSCs to model CEP290-LCA. The intronic c.
2291+1665A>G mutation leads to a premature stop codon resulting in reduction in protein 
levels, although crucially there are residual amounts of wild-type mRNA leading to some 
full length protein expression [27]. The mis-splicing of CEP290 leads to reduced ciliation of 
cells and those cilia that are still present are shorter, even in fibroblasts, despite the 
expression of 40-50% of the correct wild-type exon 26-27 transcript [27,53,57]. 
Nevertheless, why a reduction in CEP290 of approximately 50% (the same that is present in 
carriers of null mutations that have no retinal phenotype) leads to LCA is unclear. To resolve 
this paradox we differentiated homozygous c.2291+1665A>G patient iPSC into RPE and 3D 
optic cups and compared cryptic splicing levels between cell types. The CEP290-LCA iPSC 
had reduced cilia incidence, but this did not affect their differentiation, which is expected 
given the phenotype of LCA but perhaps surprising given the importance of cilia for 
signalling during development. The comparison of the different cell types showed that optic 
cups had the highest levels of aberrant splicing and cilia defects, indicating that the retina 
has a much greater reduction of CEP290 levels than other tissues, including RPE, suggesting 
this is the underlying reason for LCA and not syndromic disease [53]. Interestingly, the 
increase in mis-spliced CEP290 coincided with photoreceptor differentiation and the 
splicing of other photoreceptor specific exons. RNA-Seq of human retina suggests that 
photoreceptors have exceptionally high levels of alternative exon usage [58] and the 
increased aberrant splicing in CEP290 might be a direct consequence of this attempt to 
maximise their genome.
CEP290-LCA iPSC retinal progenitors have also been used to test the potential of a gene 
replacement approach for CEP290 [59]. This study used lentivirus, as it has a higher 
packaging capacity compared to adeno-associated virus (AAV), which cannot package a 
large gene like CEP290 (8kb). The transduction of patient retinal progenitor cells with full-
length-CEP290 lentivirus restored CEP290 mRNA expression, suggesting this approach 
might be potentially beneficial for patients in the future [59].
AON technology has previously been shown to reduce aberrant splicing in CEP290-LCA 
fibroblasts, leading to an increase in cilia incidence and cilia length in patient cells [57,60]. 
Moreover, a recent study assessed the AAV-mediated delivery of AON to the humanized 
mouse model of CEP290-LCA [61]. The AAV-CEP290 AON resulted in corrected splicing 
and decrease in the cryptic exon formation in the mouse retina [61].
We tested an AON approach in CEP290-LCA optic cups using an antisense morpholino to 
the cryptic splice site in CEP290 c.2291+1665A>G (CEP290-MO). Treatment with 
CEP290-MO reduced mis-splicing and increased the level of normal transcripts to around 
50%, which led to increased ciliation, cilia length and improvement of the cilia trafficking of 
essential photoreceptor cilia proteins, such as RPGR [53]. This study highlights further the 
potential of using 3D organoids to produce human retinal cells in an appropriate cellular 
environment to model the effects of gene-specific mutations.
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Collectively, these data and experimental models highlight that iPSC derived retinal cells 
offer a new paradigm to study retinal ciliopathy disease mechanisms and test potential 
therapies. Moreover, given that these proof of concept studies can show efficacy and safety 
in the correct human target cells they also provide the hope of a rapid translation to the 
clinic.
Acknowledgements
This research is supported by The Guide Dogs for the Blind, Fight for Sight, Moorfields Eye Charity, the Rosetrees 
Trust, the London Project to Cure Blindness, the Special Trustees of Moorfields Eye Hospital, The Wellcome Trust 
and National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital 
NHS Foundation Trust and UCL Institute of Ophthalmology.
References
[1]. Masland RH. The neuronal organization of the retina. Neuron. 2012; 76:266–80. [PubMed: 
23083731] 
[2]. Young RW. The renewal of photoreceptor cell outer segments. J Cell Biol. 1967; 33:61–72. 
[PubMed: 6033942] 
[3]. Pazour GJ, Rosenbaum JL. Intraflagellar transport and cilia-dependent diseases. Trends Cell Biol. 
2002; 12:551–5. [PubMed: 12495842] 
[4]. Adams M, Smith UM, Logan CV, Johnson CA. Recent advances in the molecular pathology, cell 
biology and genetics of ciliopathies. J Med Genet. 2008; 45:257–67. [PubMed: 18178628] 
[5]. Mockel A, Perdomo Y, Stutzmann F, Letsch J, Marion V, Dollfus H. Retinal dystrophy in Bardet-
Biedl syndrome and related syndromic ciliopathies. Prog Retin Eye Res. 2011; 30:258–74. 
[PubMed: 21477661] 
[6]. Rachel RA, et al. CEP290 alleles in mice disrupt tissue-specific cilia biogenesis and recapitulate 
features of syndromic ciliopathies. Hum Mol Genet. 2015; 24:3775–91. [PubMed: 25859007] 
[7]. Athanasiou D, Aguila M, Bevilacqua D, Novoselov SS, Parfitt DA, Cheetham ME. The cell stress 
machinery and retinal degeneration. FEBS Lett. 2013; 587:2008–17. [PubMed: 23684651] 
[8]. Hardcastle AJ, et al. Mutations in the RP2 gene cause disease in 10% of families with familial X-
linked retinitis pigmentosa assessed in this study. Am J Hum Genet. 1999; 64:1210–5. [PubMed: 
10090907] 
[9]. Dandekar SS, et al. An atypical phenotype of macular and peripapillary retinal atrophy caused by a 
mutation in the RP2 gene. Br J Ophthalmol. 2004; 88:528–32. [PubMed: 15031171] 
[10]. Koenekoop RK. An overview of Leber congenital amaurosis: a model to understand human 
retinal development. Surv Ophthalmol. 2004; 49:379–98. [PubMed: 15231395] 
[11]. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, 
proteins and disease mechanisms. Prog Retin Eye Res. 2008; 27:391–419. [PubMed: 18632300] 
[12]. Veltel S, Gasper R, Eisenacher E, Wittinghofer A. The retinitis pigmentosa 2 gene product is a 
GTPase-activating protein for Arf-like 3. Nat Struct Mol Biol. 2008; 15:373–80. [PubMed: 
18376416] 
[13]. Schwarz N, Hardcastle AJ, Cheetham ME. Arl3 and RP2 mediated assembly and traffic of 
membrane associated cilia proteins. Vision Res. 2012; 75:2–4. [PubMed: 22884633] 
[14]. Grayson C, et al. Localization in the human retina of the X-linked retinitis pigmentosa protein 
RP2, its homologue cofactor C and the RP2 interacting protein Arl3. Hum Mol Genet. 2002; 
11:3065–74. [PubMed: 12417528] 
[15]. Evans RJ, Schwarz N, Nagel-Wolfrum K, Wolfrum U, Hardcastle AJ, Cheetham ME. The 
retinitis pigmentosa protein RP2 links pericentriolar vesicle transport between the Golgi and the 
primary cilium. Hum Mol Genet. 2010; 19:1358–67. [PubMed: 20106869] 
[16]. Grayson C, Chapple JP, Willison KR, Webster AR, Hardcastle AJ, Cheetham ME. In vitro 
analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J Med 
Genet. 2002; 39:62–7. [PubMed: 11826029] 
Parfitt et al. Page 6









[17]. Hurd T, et al. The retinitis pigmentosa protein RP2 interacts with polycystin 2 and regulates cilia-
mediated vertebrate development. Hum Mol Genet. 2010; 19:4330–44. [PubMed: 20729296] 
[18]. Shu X, Zeng Z, Gautier P, Lennon A, Gakovic M, Cheetham ME, Patton EE, Wright AF. 
Knockdown of the zebrafish ortholog of the retinitis pigmentosa 2 (RP2) gene results in retinal 
degeneration. Invest Ophthalmol Vis Sci. 2011; 52:2960–6. [PubMed: 21282572] 
[19]. Patil SB, Hurd TW, Ghosh AK, Murga-Zamalloa CA, Khanna H. Functional analysis of retinitis 
pigmentosa 2 (RP2) protein reveals variable pathogenic potential of disease-associated missense 
variants. PLoS One. 2011; 6:e21379. [PubMed: 21738648] 
[20]. Liu F, et al. Knockout of RP2 decreases GRK1 and rod transducin subunits and leads to 
photoreceptor degeneration in zebrafish. Hum Mol Genet. 2015; 24:4648–59. [PubMed: 
26034134] 
[21]. Li L, et al. Ablation of the X-linked retinitis pigmentosa 2 (Rp2) gene in mice results in opsin 
mislocalization and photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2013; 54:4503–11. 
[PubMed: 23745007] 
[22]. Zhang H, et al. Mistrafficking of prenylated proteins causes retinitis pigmentosa 2. FASEB J. 
2015; 29:932–42. [PubMed: 25422369] 
[23]. Chang B, et al. In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs 
its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse. Hum 
Mol Genet. 2006; 15:1847–57. [PubMed: 16632484] 
[24]. Tsang WY, Bossard C, Khanna H, Peranen J, Swaroop A, Malhotra V, Dynlacht BD. CP110 
suppresses primary cilia formation through its interaction with CEP290, a protein deficient in 
human ciliary disease. Dev Cell. 2008; 15:187–97. [PubMed: 18694559] 
[25]. Yang TT, Su J, Wang WJ, Craige B, Witman GB, Tsou MF, Liao JC. Superresolution Pattern 
Recognition Reveals the Architectural Map of the Ciliary Transition Zone. Sci Rep. 2015; 
5:14096. [PubMed: 26365165] 
[26]. Coppieters F, Lefever S, Leroy BP, De Baere E. CEP290, a gene with many faces: mutation 
overview and presentation of CEP290base. Hum Mutat. 2010; 31:1097–108. [PubMed: 
20690115] 
[27]. Drivas TG, Wojno AP, Tucker BA, Stone EM, Bennett J. Basal exon skipping and genetic 
pleiotropy: A predictive model of disease pathogenesis. Sci Transl Med. 2015; 7:291ra97.
[28]. den Hollander AI, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber 
congenital amaurosis. Am J Hum Genet. 2006; 79:556–61. [PubMed: 16909394] 
[29]. Garanto A, van Beersum SE, Peters TA, Roepman R, Cremers FP, Collin RW. Unexpected 
CEP290 mRNA splicing in a humanized knock-in mouse model for Leber congenital amaurosis. 
PLoS One. 2013; 8:e79369. [PubMed: 24223178] 
[30]. Tucker BA, Mullins RF, Stone EM. Stem cells for investigation and treatment of inherited retinal 
disease. Hum Mol Genet. 2014; 23:R9–R16. [PubMed: 24647603] 
[31]. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult 
fibroblast cultures by defined factors. Cell. 2006; 126:663–76. [PubMed: 16904174] 
[32]. Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem 
cells. Curr Opin Genet Dev. 2012; 22:509–16. [PubMed: 22868174] 
[33]. Giacalone JC, Wiley LA, Burnight ER, Songstad AE, Mullins RF, Stone EM, Tucker BA. 
Concise Review: Patient-Specific Stem Cells to Interrogate Inherited Eye Disease. Stem Cells 
Transl Med. 2016; 5:132–40. [PubMed: 26683869] 
[34]. Vugler A, et al. Elucidating the phenomenon of HESC-derived RPE: anatomy of cell genesis, 
expansion and retinal transplantation. Exp Neurol. 2008; 214:347–61. [PubMed: 18926821] 
[35]. Carr AJ, et al. Protective effects of human iPS-derived retinal pigment epithelium cell 
transplantation in the retinal dystrophic rat. PLoS One. 2009; 4:e8152. [PubMed: 19997644] 
[36]. Carr AJ, et al. Molecular characterization and functional analysis of phagocytosis by human 
embryonic stem cell-derived RPE cells using a novel human retinal assay. Mol Vis. 2009; 
15:283–95. [PubMed: 19204785] 
[37]. Lukovic D, et al. Human iPSC derived disease model of MERTK-associated retinitis pigmentosa. 
Sci Rep. 2015; 5:12910. [PubMed: 26263531] 
Parfitt et al. Page 7









[38]. Tucker BA, Cranston CM, Anfinson KA, Shrestha S, Streb LM, Leon A, Mullins RF, Stone EM. 
Using patient-specific induced pluripotent stem cells to interrogate the pathogenicity of a novel 
retinal pigment epithelium-specific 65 kDa cryptic splice site mutation and confirm eligibility for 
enrollment into a clinical gene augmentation trial. Transl Res. 2015; 166:740–749 e1. [PubMed: 
26364624] 
[39]. Johnson AA, et al. Autosomal Recessive Bestrophinopathy Is Not Associated With the Loss of 
Bestrophin-1 Anion Channel Function in a Patient With a Novel BEST1 Mutation. Invest 
Ophthalmol Vis Sci. 2015; 56:4619–30. [PubMed: 26200502] 
[40]. Meyer JS, et al. Optic vesicle-like structures derived from human pluripotent stem cells facilitate 
a customized approach to retinal disease treatment. Stem Cells. 2011; 29:1206–18. [PubMed: 
21678528] 
[41]. Jin ZB, Okamoto S, Xiang P, Takahashi M. Integration-free induced pluripotent stem cells 
derived from retinitis pigmentosa patient for disease modeling. Stem Cells Transl Med. 2012; 
1:503–9. [PubMed: 23197854] 
[42]. Yoshida T, et al. The use of induced pluripotent stem cells to reveal pathogenic gene mutations 
and explore treatments for retinitis pigmentosa. Mol Brain. 2014; 7:45. [PubMed: 24935155] 
[43]. Sasai Y. Next-generation regenerative medicine: organogenesis from stem cells in 3D culture. 
Cell Stem Cell. 2013; 12:520–30. [PubMed: 23642363] 
[44]. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using 
organoid technologies. Science. 2014; 345:1247125. [PubMed: 25035496] 
[45]. Yin X, Mead BE, Safaee H, Langer R, Karp JM, Levy O. Engineering Stem Cell Organoids. Cell 
Stem Cell. 2016; 18:25–38. [PubMed: 26748754] 
[46]. Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, McMillan EL, Zhang SC, Gamm 
DM. Modeling early retinal development with human embryonic and induced pluripotent stem 
cells. Proc Natl Acad Sci U S A. 2009; 106:16698–703. [PubMed: 19706890] 
[47]. Lamba DA, McUsic A, Hirata RK, Wang PR, Russell D, Reh TA. Generation, purification and 
transplantation of photoreceptors derived from human induced pluripotent stem cells. PLoS One. 
2010; 5:e8763. [PubMed: 20098701] 
[48]. Nakano T, et al. Self-formation of optic cups and storable stratified neural retina from human 
ESCs. Cell Stem Cell. 2012; 10:771–85. [PubMed: 22704518] 
[49]. Zhong X, et al. Generation of three-dimensional retinal tissue with functional photoreceptors 
from human iPSCs. Nat Commun. 2014; 5:4047. [PubMed: 24915161] 
[50]. Reichman S, et al. From confluent human iPS cells to self-forming neural retina and retinal 
pigmented epithelium. Proc Natl Acad Sci U S A. 2014; 111:8518–23. [PubMed: 24912154] 
[51]. Gonzalez-Cordero A, et al. Photoreceptor precursors derived from three-dimensional embryonic 
stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol. 2013; 
31:741–7. [PubMed: 23873086] 
[52]. Tucker BA, et al. Patient-specific iPSC-derived photoreceptor precursor cells as a means to 
investigate retinitis pigmentosa. Elife. 2013; 2:e00824. [PubMed: 23991284] 
[53]. Parfitt DA, et al. Identification and Correction of Mechanisms Underlying Inherited Blindness in 
Human iPSC-Derived Optic Cups. Cell Stem Cell. 2016
[54]. Hockemeyer D, Jaenisch R. Induced Pluripotent Stem Cells Meet Genome Editing. Cell Stem 
Cell. 2016; 18:573–86. [PubMed: 27152442] 
[55]. Schwarz N, et al. Translational read-through of the RP2 Arg120stop mutation in patient iPSC-
derived retinal pigment epithelium cells. Hum Mol Genet. 2015; 24:972–86. [PubMed: 
25292197] 
[56]. Schwarz N, Novoselova TV, Wait R, Hardcastle AJ, Cheetham ME. The X-linked retinitis 
pigmentosa protein RP2 facilitates G protein traffic. Hum Mol Genet. 2012; 21:863–73. 
[PubMed: 22072390] 
[57]. Collin RW, den Hollander AI, van der Velde-Visser SD, Bennicelli J, Bennett J, Cremers FP. 
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a 
Frequent Mutation in CEP290. Mol Ther Nucleic Acids. 2012; 1:e14. [PubMed: 23343883] 
[58]. Farkas MH, Grant GR, White JA, Sousa ME, Consugar MB, Pierce EA. Transcriptome analyses 
of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed 
Parfitt et al. Page 8









sequence via significant alternative splicing and novel genes. BMC Genomics. 2013; 14:486. 
[PubMed: 23865674] 
[59]. Burnight ER, et al. CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype. 
Gene Ther. 2014; 21:662–72. [PubMed: 24807808] 
[60]. Gerard X, et al. AON-mediated Exon Skipping Restores Ciliation in Fibroblasts Harboring the 
Common Leber Congenital Amaurosis CEP290 Mutation. Mol Ther Nucleic Acids. 2012; 1:e29. 
[PubMed: 23344081] 
[61]. Garanto A, et al. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by 
antisense oligonucleotide delivery. Hum Mol Genet. 2016
Parfitt et al. Page 9









Figure 1. Rudimentary outer segments in iPSC 3D organoid optic cups.
(A) Rhodopsin localization (green) in 145 day old control iPSC derived optic cups. 
Rhodopsin immunoreactivity is most intense in the rudimentary outer segments (OS, and *). 
The inner segments (IS and separated from the outer nuclear layer stained with DAPI (blue) 
by the outer limiting membrane (OLM; highlighted with arrows). Immature photoreceptors 
have still have strong immunoreactivity in the IS and ONL. Note the rudimentary OS tend to 
break during processing. (B) Magnified OS stained with rhodopsin (green), the base of the 
cilium is highlighted with rootletin (red, R) highlighting the connecting cilum (CC) between 
the two. Scale bars = 10μm (A) and 2μm (B)
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